MARKET

PROK

PROK

ProKidney
NASDAQ
2.150
-0.010
-0.46%
After Hours: 2.132 -0.018 -0.84% 19:23 05/02 EDT
OPEN
2.160
PREV CLOSE
2.160
HIGH
2.230
LOW
2.125
VOLUME
351.40K
TURNOVER
0
52 WEEK HIGH
13.51
52 WEEK LOW
1.120
MARKET CAP
498.15M
P/E (TTM)
-3.7411
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PROK last week (0422-0426)?
Weekly Report · 4d ago
MRIN, WISA and SMFL among mid-day movers
On the Move MRIN, WISA and SMFL among mid-day movers in SA. Matterport, mF International and Edible Garden AG are among the Gainers. YY Group Holding Limited is one of the losers in SA's top 10 list of companies.
Seeking Alpha · 04/22 16:52
12 Health Care Stocks Moving In Monday's Intraday Session
NKGen Biotech (NASDAQ:NKGN) shares rose 33.8% to $1.48 during Monday's regular session. The company's, Q4 earnings came out 4 days ago. MSP Recovery shares rose 29.74% and Assure Hldgs stock increased by 24.31%. Losers include Vaxxinity, Ocean Biomedical and Telomir Pharmaceuticals.
Benzinga · 04/22 16:31
Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers
Healthcare On the Move: Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers. S&P 500 Health Care Sector +0.08% to 1620.1. Moolec Science SA, NKGen Biotech, ProKidney among top gainers.
Seeking Alpha · 04/22 14:01
Weekly Report: what happened at PROK last week (0415-0419)?
Weekly Report · 04/22 11:02
Veru, EyePoint Pharmaceuticals, SINTX Technologies among healthcare movers
Seeking Alpha · 04/18 14:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Trevena (NASDAQ:TRVN) shares increased by 27.0% to $0.51 during Wednesday's after-market session. Mustang Bio stock increased by 11.97% and SINTX Techs stock rose 10.32% in the same session. Losers TRACON Pharma and DIH Holding US stock fell by 16.6% and 14.05% respectively.
Benzinga · 04/17 20:31
Lexaria Bioscience, Biosig Technologies, BIMI Holdings among healthcare movers
Seeking Alpha · 04/17 14:00
More
About PROK
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).

Webull offers ProKidney Corp stock information, including NASDAQ: PROK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PROK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PROK stock methods without spending real money on the virtual paper trading platform.